Abstract 522P
Background
Adding an immune checkpoint inhibitor (ICI) to chemotherapy has demonstrated efficacy in treating extensive-stage small cell lung cancer (ES-SCLC). However, patients with idiopathic interstitial pneumonia (IIP) have a higher risk of developing pneumonitis associated with anticancer therapy. We conducted a multicenter, single-arm trial to evaluate the safety and efficacy of durvalumab plus etoposide and carboplatin for patients with ES-SCLC and mild IIP.
Methods
Eligible patients were those who had not been previously treated with ES-SCLC and mild IIPs. Mild IIP was defined as predicted vital capacity (VC) ≥80%; no collagen vascular disease-associated antibodies; and chest high-resolution computed tomography image revealed a probable UIP, indeterminate for UIP, or alternative diagnosis pattern. The primary endpoint was severe-pneumonitis-free (SPF) rate, which was defined as the rate of patients who did not develop Grade 3 or higher pneumonitis. The study treatment was feasible if the SPF rate was 90% or more, and grade 5 pneumonitis was found within one patient.
Results
In total, 22 cases were enrolled, and 21 were included in the analysis. The median age was 74 years (range, 65–82). Most patients had stage Ⅳ disease (90%) and Eastern Cooperative Oncology Group Performance Status of 1 (67%). The median %VC was 96.1% (range 81.3–117.8). Thirteen patients displayed a probable UIP pattern, while 8 were indeterminate for UIP pattern. The SPF rate was 95.2% (20/21). The incidence of pneumonitis was 9.5% (2/21) for all grades. One patient had grade 5 pneumonitis.
Conclusions
Durvalumab plus etoposide and carboplatin can be a feasible treatment option for patients with ES-SCLC and mild IIPs.
Clinical trial identification
The Japan Registry of Clinical Trials: jRCTs051200109.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca PLC.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
471TiP - A group sequential, response-adaptive randomized double-blinded clinical trial to evaluate add-on olanzapine plus pregabalin to prevent chemotherapy-induced nausea and vomiting (CINV ) in patients belonging to low socio-economic status
Presenter: Mathan Ramasubbu
Session: Poster Display
Resources:
Abstract
472P - Risk of recurrence and optimal adjuvant treatment in invasive lung adenocarcinomas manifesting as radiological part-solid nodules
Presenter: Yang Wo
Session: Poster Display
Resources:
Abstract
473P - Treatment (tx) patterns in resectable stage IA–IIIA non-small cell lung cancer (NSCLC) in China: Subgroup analysis of a global real-world (rw) study
Presenter: Chih-Chi Yang
Session: Poster Display
Resources:
Abstract
474P - The efficacy of image guided coil localisation for surgical resection of undiagnosed solitary lung nodule
Presenter: Jun Rey Leong
Session: Poster Display
Resources:
Abstract
475P - 5-year overall survival and disease free survival outcome between lobectomy and segmentectomy for early stage lung cancer in a mixed Asian population
Presenter: Jianye Chen
Session: Poster Display
Resources:
Abstract
478P - Peri-operative risks in curative lung resection of early stage primary lung cancer patients above 70 years old in a mixed Asian population
Presenter: Ian Goh
Session: Poster Display
Resources:
Abstract
480P - Aumolertinib as adjuvant therapy for resectable stage I-III EGFR-mutant NSCLC: Also effective in EGFR co-mutation
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
481P - Comparative analysis of three NGS platforms assessing tumor mutational burden and mutational landscape in resectable non-small cell lung cancer
Presenter: Jii Bum Lee
Session: Poster Display
Resources:
Abstract
482P - Prevalence of EGFR mutations (EGFRm) and its subtypes in patients (pts) with resected stage I-III NSCLC: Results from EARLY-EGFR Singapore cohort
Presenter: Puey Ling Chia
Session: Poster Display
Resources:
Abstract
483P - Genetic profiles and evolutionary trajectory of early stage lung adenocarcinoma (AAH, AIS, MIA and IAC) revealed by multiplex sequecing
Presenter: lixuan lin
Session: Poster Display
Resources:
Abstract